Novartis Investigative Site

Riverside, California 92506

0 studies enrolling now · 22 studies all time

What they study most

Age-related Macular Degeneration, Asthma, COPD, Cardiovascular Disease, Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease (COPD), Diabetes, Diabetic Macular Edema, Hypertension, Ovarian Cancer, Stage 2 Hypertension, Type 2 Diabetes Mellitus

Studies at this site

• Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON) — Completed
• Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema — Completed
• Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe Asthma — Completed
• Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer — Completed
• Dose Finding Study for QAW039 in Asthma — Completed
• Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment. — Completed
• A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With Asthma — Completed
• Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients. — Completed
• Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma — Completed
• A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients — Completed
• A Study to Establish the Efficacy of QBX258 in Patients With Moderate to Severe Asthma — Completed
• A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation. — Completed
• Long Term Safety Study of NVA237 vs QAB149 in COPD Patients — Completed
• A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation — Completed
• NVA237 Versus Placebo 12-week Efficacy Study — Completed
• Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases) — Stopped early
• 8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension — Completed
• Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations — Completed
• A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) — Completed
• Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes — Stopped early
• Safety, Tolerability and Efficacy of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) — Completed
• Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) — Completed